Full-Time

Procurement Specialist

Revvity

Revvity

1,001-5,000 employees

Translational multi-omics and diagnostics provider

No salary listed

Mumbai, Maharashtra, India

In Person

Some travel may be required to vendor locations or other Revvity sites.

Bachelor's

Category
Operations & Logistics (1)
Required Skills
ERP
Inventory Management
Forecasting
SAP Products
Word/Pages/Docs
Oracle
Data Analysis
Database Administration
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Revvity

See people who can refer or advise you

Requirements
  • A bachelor's degree from a four-year college or university is desired, with one to three years of related experience or training, or equivalent education and experience.
  • At least five years of experience in a manufacturing environment is required; life sciences experience is preferred.
  • Ability to write reports, business correspondence, and purchase specifications, and to present information and respond to inquiries from management, suppliers, and customers.
  • Ability to calculate figures and amounts such as discounts, interest, commissions, proportions, percentages, area, circumference, and volume.
  • Highly effective time management skills.
  • Commitment to customer excellence with demonstrated ethics and integrity.
  • Ability to operate independently and as part of a team.
  • Working knowledge of enterprise resource planning systems such as SAP or Oracle.
  • Ability to use Excel, including creating pivot tables and graphs for data analysis.
  • Ability to use Word.
  • Ability to create presentations using PowerPoint.
  • Access knowledge is a plus.
Responsibilities
  • Use an enterprise resource planning system, including SAP and SAP Advanced Planning and Optimization, to develop near-term and long-term production plans.
  • Plan an original equipment manufacturer and/or manufactured product portfolio and maintain forecast performance and stock levels at local and international forward-stocking sites.
  • Purchase materials according to business guidelines, maintain vendor masters and supplier performance metrics, and evaluate new suppliers.
  • Review purchase requisitions and enterprise resource planning output for appropriate information and approvals.
  • Obtain product or service information from suppliers, including price, availability, and delivery schedules.
  • Work with manufacturing to maintain parity between costing and bill of materials and routing changes.
  • Run and send suppliers open-order, past-due-order, supplier-requirements, and Kanban reports as required.
  • Enter and reschedule purchase orders in the enterprise resource planning system in a timely manner.
  • Interface directly with internal customers, product managers, customer care, manufacturing partners, and suppliers to resolve order status, discrepancies, past-due items, and schedule or date changes.
  • Resolve invoice discrepancies with suppliers and Accounts Payable.
  • Manage purchasing-card invoicing approvals.
  • Coordinate defective and returned materials with suppliers, Quality Assurance, and others to determine root cause and initiate and follow up on corrective actions.
  • Coordinate office-supply ordering and replenishment.
  • Run, compile, and distribute reports and databases related to inventory, open purchase orders, and suppliers.
  • Develop and administer reports and databases to support multiple business functions as required.
  • Analyze data and structure reports using planning concepts, analytical skills, and computer skills.
  • Perform licensing reviews or similar functions associated with material procurement, material requirements planning and enterprise resource planning systems, and vendor requirements as necessary.
  • Cross-train into other areas as needed.
Desired Qualifications
  • Life sciences experience.
  • Demonstrated analytical skills and the ability to communicate data points across a multi-level audience.
  • Ability to communicate and collaborate with peers and colleagues, including cross-functional global partners, and actively and constructively resolve conflict.
  • Experience driving continuous improvement efforts to optimize efficiency.
  • Strong project management skills using software such as Microsoft Project or Excel, with the ability to communicate status updates and process-improvement efforts clearly and concisely to senior leaders.
  • Experience working in a global, matrix environment.
  • Highly collaborative and organized, with strong attention to detail.
  • Comfort with ambiguity and ability to work in a self-guided manner.

Revvity provides health science solutions that span the full journey from discovery to development and from diagnosis to cure. It offers translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics, all delivered as integrated workflows and expert services. The company differentiates itself with an end-to-end platform that combines omics, imaging, biomarkers, and data analytics with specialized support to speed development. Its goal is to turn previously impossible healthcare outcomes into achievable results, advancing discovery, development, diagnosis and patient care.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2023

Get referred to Revvity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $730 million, with 3% organic growth and raised guidance.
  • Signals for Startups launched July 2026, opening enterprise software sales to seed-stage biotechs.
  • SuperFlex and T-SPOT A201 expand Revvity's menu into prenatal and infectious-disease testing.

What critics are saying

  • China Immunodiagnostics was 6% of 2025 revenue; divestiture closes only by end-2027.
  • T-SPOT A201 still needs regulatory approval and a second-half 2027 launch.
  • Diagnostics growth slowed to 3% organic in Q2 2026, leaving Revvity dependent on execution.

What makes Revvity unique

  • Revvity owns both diagnostics and Signals software, spanning discovery, screening, and clinical workflows.
  • SuperFlex targets lower-volume labs with CE-IVDR automation, filling a neglected prenatal screening niche.
  • T-SPOT A201 extends Revvity's proprietary latent TB franchise into high-throughput automation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Company Match

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

4%
Yahoo Finance
Aug 13th, 2026
Revvity launches SuperFlex prenatal screening system for smaller labs

Revvity has launched SuperFlex, a compact prenatal screening system designed for small and mid-sized laboratories. The CE-IVDR-certified automated immunoassay instrument will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. The benchtop immunoanalyser processes up to 60 tests per hour and delivers initial results in 14 minutes. It supports preeclampsia screening and prenatal testing using chemiluminescence immunoassay technology with 24 sample positions. SuperFlex aims to address financial and operational barriers in lower-volume testing environments by offering lower instrument costs, reduced maintenance expenses, and no reagent wastage. The platform integrates with Revvity's LifeCycle software. Revvity shares gained 1.6% following the announcement and have risen 21.8% year-to-date. The company has a market capitalisation of $12.91 billion.

Associated Press
Aug 10th, 2026
Revvity launches SuperFlex system to expand preeclampsia screening access in lower-volume labs

Revvity has launched the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed for laboratories and clinics with lower-volume workflows. The system tests for preeclampsia, which affects 2% to 8% of pregnancies globally. The platform features affordable instrument costs with annual maintenance, no reagent wastage at low volumes, and delivers results in as little as 14 minutes per test. It includes a test menu for first- and second-trimester biochemical prenatal screening. The system will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. Revvity reported 2025 revenue of $2.9 billion and employs approximately 11,000 people.

Yahoo Finance
Aug 10th, 2026
Upstart named buy amid 30.6% revenue growth forecast, Revvity and Northern Trust flagged as risky

Upstart, an AI-powered lending platform, stands out as a buy opportunity among profitable stocks, according to StockStory's analysis. The company uses machine learning to assess borrower risk for various loan types. Upstart's loan originations surged 54.3% over the past year, enabling increased fee collection and expansion into new markets like credit cards. The company's revenue is expected to grow 30.6% over the next 12 months, with free cash flow anticipated to turn positive next year. Meanwhile, StockStory advises caution on Revvity and Northern Trust. Revvity's sales declined 10.6% annually over five years, whilst Northern Trust's 6.9% annual revenue growth lagged behind financial peers. Both companies face headwinds despite maintaining profitability, with earnings pressures and market share concerns affecting their outlooks.

Yahoo Finance
Aug 4th, 2026
Revvity reports $730M Q2 revenue, 4% growth, and raises full-year guidance

Revvity reported second quarter 2026 revenue of $730 million, with pro forma revenue of $711 million representing 4% growth and 3% organic growth. The company posted GAAP earnings per share from continuing operations of $0.48, while adjusted EPS reached $1.41. The company announced a definitive agreement to divest its China Immunodiagnostics business, which accounted for approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals. Adjusted operating profit margin improved to 28.9%, up from 26.6% in the prior year period. GAAP operating income included $16 million in tariff-related refunds. Revvity raised its full-year guidance following the results.

Rompa Group
Jul 28th, 2026
A meaningful gift marks a milestone moment at Rompa CZ.

A meaningful gift marks a milestone moment at Rompa CZ. Rompa now has a lasting reminder of the opening ceremony for its new Class 7 cleanroom facility in the Czech Republic, in the form of a thoughtful symbolic gift from its customer, the biotechnology company Revvity. This special artwork connects the event to the wider story of Life Sciences research, and was presented by Revvity's Managing Director, Jochem Bruggeman, to Marcos Valladolid, Rompa's COO. The story behind the artwork. The art was created using Revvity's own instruments and depicts HeLa cells, which hold a unique place in biomedical research. They were the first human cells successfully grown continuously in a laboratory and remain one of the most widely used cell lines in science today. Originally taken from Henrietta Lacks in 1951, HeLa cells have contributed to thousands of scientific breakthroughs over more than 75 years of research. They have played an important role in areas including vaccine development, cancer research, virology, drug screening, gene mapping and many other fields of biomedical science. The story of HeLa cells is also an important reminder of the ethical responsibilities that come with scientific progress. Henrietta Lacks' cells were used without her knowledge or consent, raising questions about patient rights, informed consent and the use of biological materials in research. Those discussions continue to influence how biomedical research is conducted today. Celebrating a long-standing partnership with Revvity. For Rompa, the present is a symbol of the partnership between its two companies and of the Life Sciences work now taking place inside the new cleanroom. The gift also marks Rompa's longstanding partnership with Revvity, whose products are among the first being produced in the new ISO Class 7 cleanroom at Rompa CZ. This made the opening ceremony not only a celebration of a new facility, but also a celebration of the collaboration, trust and shared commitment that helped bring the project to life. The cleanroom is designed to support multiple integrated production lines, including automated manufacturing solutions for microplate production. It enables Rompa to support customers with demanding applications in healthcare, diagnostics and other highly regulated Life Sciences markets. Rompa Group is grateful to Revvity for such a thoughtful gesture, and to everyone who joined Rompa Group to mark this important moment for Rompa CZ. As the artwork reminds Rompa Group, progress in Life Sciences depends on precision, partnership and respect for the scientific work that helps improve lives. Rompa Group is proud that its new cleanroom will play a part in supporting that work for years to come.